Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 30+ AI models, with 0% extra fees
Why IDEXX Laboratories Stock Is Undervalued at $561 in 2026
IDEXX Laboratories (IDXX) is considered undervalued despite recent strong Q4 2025 revenue growth of 14%, driven by record premium instrument placements, particularly its AI-powered inVue Dx analyzers. Wall Street analysts and TIKR’s model project significant upside potential, with a median target of $788 and a mid-case model target of $919 by 2030, owing to recurring revenue commitments, expanding operating margins, and product innovations like the Cancer Dx panel. The investment thesis hinges on continued strong adoption of new diagnostic platforms and a recovery in veterinary visits, balancing against potential risks like deeper declines in U.S. clinical visits.